Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases and cancer.
Company Growth (employees)
Type
Public
HQ
Boston, US
Founded
1989
Size (employees)
2,150 (est)
Website
vrtx.com
Vertex Pharmaceuticals was founded in 1989 and is headquartered in Boston, US

Vertex Pharmaceuticals Office Locations

Vertex Pharmaceuticals has an office in Boston
Boston, US (HQ)
50 Northern Ave

Vertex Pharmaceuticals Financials and Metrics

Vertex Pharmaceuticals Financials

Vertex Pharmaceuticals's revenue was reported to be $1.7 b in FY, 2016
USD

Revenue (Q2, 2017)

544.1 m

Net income (Q2, 2017)

31.2 m

EBIT (Q2, 2017)

52.7 m

Market capitalization (13-Dec-2017)

36.2 b

Cash (30-Jun-2017)

1.2 b
Vertex Pharmaceuticals's current market capitalization is $36.2 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.2 b580.4 m1 b1.7 b

Revenue growth, %

(52%)78%65%

R&D expense

1 b

Operating expense total

1 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

221.7 m118.5 m138.4 m179 m138.5 m166.1 m309.8 m398.1 m431.6 m413.8 m714.7 m544.1 m

R&D expense

228.6 m239 m224.8 m190.9 m215.6 m223.9 m246.3 m255.9 m271 m272.4 m273.6 m289.5 m

Operating expense total

355.8 m334.8 m319.3 m321.2 m310.5 m337.2 m379.8 m412.4 m428.3 m432.5 m443.9 m491.4 m

EBIT

(134.1 m)(216.4 m)(180.8 m)(142.2 m)(172 m)(171.2 m)(70 m)(14.3 m)3.4 m(18.7 m)270.8 m52.7 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

569.3 m625.3 m714.8 m1.2 b

Accounts Receivable

85.5 m76 m177.6 m201.1 m

Inventories

14.1 m30.8 m57.2 m77.6 m

Current Assets

1.6 b1.5 b1.4 b1.8 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

583.2 m424 m420.6 m718.6 m664.9 m870.5 m756.3 m604.2 m605.9 m719.7 m1 b1.2 b

Accounts Receivable

120.3 m59.9 m81.8 m114.3 m80.3 m94.5 m165.3 m181.9 m189.4 m182.2 m208 m247.9 m

Inventories

13.5 m11.3 m12 m16.8 m34.1 m42.1 m49.2 m63.2 m66.6 m71.8 m82 m92.3 m

Current Assets

1.6 b1.4 b1.3 b1.7 b1.4 b1.3 b1.4 b1.4 b1.5 b1.5 b1.9 b2.2 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(687.6 m)(742.7 m)(588.2 m)(84 m)

Depreciation and Amortization

48.4 m63.3 m62.3 m61.4 m

Accounts Receivable

53.4 m7.4 m(100 m)(33 m)

Inventories

7.1 m(16 m)(23 m)(16.5 m)
USDQ3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(128.7 m)(232.5 m)(159.4 m)(198.7 m)(391.8 m)(561.9 m)(36.1 m)(72.3 m)(111.8 m)249.5 m(72.3 m)

Depreciation and Amortization

16.4 m31.4 m45.9 m14.9 m

Accounts Receivable

94.5 m165.3 m(2.5 m)(13 m)(9.8 m)(5.1 m)

Inventories

42.1 m49.2 m(4.8 m)(7.8 m)(11.5 m)(3.7 m)
USDY, 2017

Revenue/Employee

253.1 k

Financial Leverage

1.8 x
Show all financial metrics

Vertex Pharmaceuticals Market Value History

Vertex Pharmaceuticals's Web-traffic and Trends

Vertex Pharmaceuticals Online and Social Media Presence

Vertex Pharmaceuticals Company Life and Culture

You may also be interested in